Cargando…

Hepatic protein tyrosine phosphatase receptor gamma links obesity-induced inflammation to insulin resistance

Obesity-induced inflammation engenders insulin resistance and type 2 diabetes mellitus (T2DM) but the inflammatory effectors linking obesity to insulin resistance are incompletely understood. Here, we show that hepatic expression of Protein Tyrosine Phosphatase Receptor Gamma (PTPR-γ) is stimulated...

Descripción completa

Detalles Bibliográficos
Autores principales: Brenachot, Xavier, Ramadori, Giorgio, Ioris, Rafael M., Veyrat-Durebex, Christelle, Altirriba, Jordi, Aras, Ebru, Ljubicic, Sanda, Kohno, Daisuke, Fabbiano, Salvatore, Clement, Sophie, Goossens, Nicolas, Trajkovski, Mirko, Harroch, Sheila, Negro, Francesco, Coppari, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703876/
https://www.ncbi.nlm.nih.gov/pubmed/29180649
http://dx.doi.org/10.1038/s41467-017-02074-2
Descripción
Sumario:Obesity-induced inflammation engenders insulin resistance and type 2 diabetes mellitus (T2DM) but the inflammatory effectors linking obesity to insulin resistance are incompletely understood. Here, we show that hepatic expression of Protein Tyrosine Phosphatase Receptor Gamma (PTPR-γ) is stimulated by inflammation in obese/T2DM mice and positively correlates with indices of inflammation and insulin resistance in humans. NF-κB binds to the promoter of Ptprg and is required for inflammation-induced PTPR-γ expression. PTPR-γ loss-of-function lowers glycemia and insulinemia by enhancing insulin-stimulated suppression of endogenous glucose production. These phenotypes are rescued by re-expression of Ptprg only in liver of mice lacking Ptprg globally. Hepatic PTPR-γ overexpression that mimics levels found in obesity is sufficient to cause severe hepatic and systemic insulin resistance. We propose hepatic PTPR-γ as a link between obesity-induced inflammation and insulin resistance and as potential target for treatment of T2DM.